PTCT Q2 2025 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$6B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$179M-4.2% YoY

Gross Profit

$167M93.6% margin

Operating Income

-$35M-19.5% margin

Net Income

-$65M-36.3% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-84.8%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$62M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$2.6B

Total Liabilities

$2.8B

Stockholders' Equity

-$207M

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$179M	$187M	-4.2%
Gross Profit	$167M	$171M	-2.2%
Operating Income	-$35M	-$40M	+13.1%
Net Income	-$65M	-$99M	+34.6%

Revenue Segments

Product

$118M66%

Royalty

$58M32%

Collaboration and License Revenue

$3M2%

Geographic Segments

Non-US

$82M69%

United States

$36M31%